7.3
Modello aperto monocompartimentale per somministrazione di bolo EV: considerazioni generali
Il modello monocompartimentale è uno strumento farmacocinetico che vede il corpo come un singolo compartimento uniforme, facilitando la comprensione d…
Un modello di farmacocinetica aperta a un compartimento descrive l'andamento della concentrazione del farmaco nel corpo dopo la somministrazione. Vede il corpo come un unico compartimento omogeneo senza barriere al movimento dei farmaci.
Il termine "aperto" indica i processi unidirezionali di input e output dei farmaci.
I farmaci attraversano dinamicamente questo compartimento, assumendo un rapido equilibrio tra il plasma e gli altri fluidi corporei. Qui, il tasso di assorbimento supera quello di eliminazione.
L'eliminazione segue un processo di primo ordine con una costante di velocità costante. Inoltre, il plasma è il compartimento di riferimento, con una variazione della concentrazione plasmatica del farmaco proporzionale alle variazioni della concentrazione tissutale del farmaco.
Questo modello è ideale per prevedere la farmacocinetica di farmaci a rapida dispersione, come la teofillina somministrata in bolo per via endovenosa, per un dosaggio sicuro ed efficace.
Il tasso di presentazione del farmaco all'organismo è definito da un'equazione che rappresenta la differenza tra il tasso di entrata e di uscita dal farmaco.
I parametri farmacocinetici possono essere calcolati direttamente dal profilo concentrazione plasmatica-tempo o utilizzando metodi non compartimentali.
View the full transcript and gain access to JoVE Core videos
Q1: What does 'open' mean in the one-compartment open model?
In the one-compartment open model, 'open' signifies unidirectional drug input and output processes. The body is viewed as a single, homogenous compartment where drugs dynamically traverse and assume rapid equilibrium between plasma and other body fluids. This contrasts with closed systems where drugs cannot leave the body.
Q2: How is elimination described in the one-compartment open model?
Elimination follows a first-order process with a consistent rate constant, meaning the rate of drug elimination is proportional to the drug concentration present. The rate of drug presentation to the body is defined by an equation representing the difference between the rate of drug entry and exit, allowing prediction of drug concentration over time.
Q3: Why is plasma the reference compartment in this model?
Plasma serves as the reference compartment because plasma drug concentration change is proportional to tissue drug concentration changes. This relationship assumes rapid equilibrium between plasma and other body fluids, allowing plasma measurements to reflect overall drug distribution and elimination throughout the body.
Q4: What are the key pharmacokinetic parameters calculated from the plasma concentration-time profile?
Key parameters include the elimination rate constant, half-life, apparent volume of distribution, and total systemic clearance. These parameters can be calculated directly from the plasma concentration-time profile or by using non-compartmental methods, providing essential information for safe and effective dosing.
Q5: Which drugs are ideal candidates for the one-compartment open model?
The one-compartment open model is ideal for rapidly dispersing drugs that are quickly and completely absorbed, such as intravenous bolus-administered theophylline and propofol. These drugs distribute rapidly throughout the body and follow first-order elimination kinetics, making them suitable for this simplified modeling approach.
Q6: What is the residuals method and how does it determine the absorption rate constant?
The residuals method separates the plasma concentration-time curve into absorption and elimination phases to determine the absorption rate constant. This approach is particularly useful for extravascular administration, where distinguishing between absorption and elimination phases is necessary for accurate pharmacokinetic parameter estimation.
Q7: How does lag time affect the plasma concentration-time profile in this model?
Lag time represents the interval between drug administration and absorption onset, delaying the appearance of drug in plasma. The model accounts for this delay, and a bi-exponential equation can define the resulting plasma concentration-time profile, ensuring accurate predictions of drug kinetics when absorption is not instantaneous.